





# 17th Annual **St. Jude/PIDS**

Pediatric Infectious Diseases Research Conference

# **Program & Abstracts** March 9–10, 2018

## Marlo Thomas Center

For Global
Education And
Collaboration
St. Jude
Children's
Research
Hospital

# 17<sup>th</sup> Annual St. Jude/PIDS Pediatric Infectious Diseases Research Conference St. Jude Children's Research Hospital March 9-10, 2018 Memphis, Tennessee

St. Jude Children's Research Hospital Department of Infectious Diseases 262 Danny Thomas Place, Mailstop 320 Memphis, TN 38105-3678

Pediatric Infectious Diseases Society 1300 Wilson Boulevard Suite 300 Arlington, VA 22209 March 7, 2018

#### Dear Colleagues:

On behalf of St. Jude Children's Research Hospital and the Pediatric Infectious Diseases Society, we welcome you to Memphis, Tennessee for the 17<sup>th</sup> Annual St. Jude/PIDS Pediatric Infectious Diseases Research Conference!

This year, nearly 200 faculty, fellows, and students will attend the meeting. The program features a "Frontiers in Infectious Diseases" symposium, with presentations from leading investigators in infectious diseases and microbiology. In addition, a series of career development workshops will be available, including sessions on career paths in public health, private practice, investigative research, and outcomes research. Perhaps most important, attendees will have an opportunity to present their original research to colleagues in pediatric infectious diseases, with over 60 novel case reports and original science abstract publications in basic and clinical science, epidemiology, laboratory diagnostics, and health outcomes. We are also pleased to announce that, through the generosity of St. Jude Children's Research Hospital, these original science abstracts will be published as a supplement in the *Journal of the Pediatric Infectious Diseases Society* (JPIDS) along with a summary of conference proceedings and selected invited reviews.

We look forward to an excellent meeting and to meeting each of you over the next few days.

Sincerely,

Elaine I. Tuomanen, MD, FPIDS Chair, Department of Infectious Diseases St. Jude Children's Research Hospital Buddy Creech, MD, MPH, FPIDS Chair, Research Affairs Committee, Pediatric Infectious Diseases Society Director, Vanderbilt Vaccine Research Program

#### **Research Affairs Committee**

Anne Blaschke, MD, PhD
Betsy Herold, MD, FPIDS
Scott James, MD
Miriam Laufer, MD
Elisa Margolis, MD, PhD
Ian Michelow, MD
William Muller, MD, PhD, FPIDS

Sallie Permar, MD, PhD Octavio Ramilo, MD, FPIDS David Rosen, MD, PhD Jessica Snowden, MD Stephen Spector, MD Joshua Wolf, MBBS

	PROGRAM AT A GLANCE	
Wednesday, March 7		
6:00 – 8:00 P.M.	Satellite Registration	
	Westin Memphis Beale Street Hotel	
Friday, March 9	Marlo Thomas Center for Global Education and Collaboration (GEC)	
7:30 A.M.	Breakfast	
8:00 A.M.	Welcome and Announcements	
	Elaine Tuomanen, MD, St. Jude Children's Research Hospital	
	Buddy Creech, MD, MPH, Vanderbilt University School of Medicine	
	Paul W. Spearman, MD, Cincinnati Children's Hospital Medical Center	
8:10 – 11:30 A.M.	Frontier Lectures in Infectious Diseases	
	Using systems serology to understand mother to child antibody transfer—Galit Alter,	
	PhD, Harvard University	
	Novel therapeutic strategies from study of host-pathogen interaction—George Liu, MD,	
	PhD, Cedars-Sinai Medical Center	
	The Future of HIV Therapeutics; Towards Sustained ART-Free Remission and Cure—	
	Deborah Persaud, MD, Johns Hopkins University	
	Multidrug resistant Enterococci, a problem foreordained by events of the Paleozoic	
	era—Michael Gilmore, PhD, Harvard University	
11:30 A.M. – 12:30 P.M.	2018 John H. Erskine Lecture in Infectious Diseases	
	Listeria monocytogenes: From basic mechanisms of pathogenesis to cancer	
	immunotherapy—Daniel Portnoy, PhD, University of California, Berkeley	
12:30 – 1:30 P.M.	Lunch – Roundtable with Faculty	
1 20 4 00 D 15		
1:30 – 4:00 P.M.	Oral Abstract Presentations by Fellowship Award Recipients	
	Dissecting mechanisms of granulomatous response in chronic bacterial  One of the control of	
	infections—Trung Pham, MD, PhD, Stanford University, Stanford, CA	
	Development of a consensus DNA vaccine for seasonal H3N2 influenza	
	viruses—Amelia Keaton, MD, The Children's Hospital of Philadelphia, PA	
	<ul> <li>Antibiotic exposure and progression of respiratory viral infections in transplant recipients—Chikara Ogimi, MD, Seattle Children's Hospital,</li> </ul>	
	Seattle, WA	
	• IgE-mediated allergic stimulation inhibits monocyte antiviral responses to alter	
	virus-induced T cell priming by influenza and rhinovirus—Regina Rowe, MD,	
	University of Texas Southwestern Medical Center, Dallas, TX	

1:30 – 4:00 P.M.	Oral Abstract Presentations by Fellowship Award Recipients		
	Dissecting mechanisms of granulomatous response in chronic bacterial		
	infections—Trung Pham, MD, PhD, Stanford University, Stanford, CA		
	<ul> <li>Development of a consensus DNA vaccine for seasonal H3N2 influenza</li> </ul>		
	viruses—Amelia Keaton, MD, The Children's Hospital of Philadelphia, PA		
	<ul> <li>Antibiotic exposure and progression of respiratory viral infections in</li> </ul>		
	transplant recipients—Chikara Ogimi, MD, Seattle Children's Hospital, Seattle, WA		
	IgE-mediated allergic stimulation inhibits monocyte antiviral responses to alter		
	virus-induced T cell priming by influenza and rhinovirus—Regina Rowe, MD,		
	University of Texas Southwestern Medical Center, Dallas, TX		
	Oral Abstracts by Meeting Attendees		
	• (19131) Maternal immunization with ΔgD-2 protects neonatal mice against		
	lethal HSV challenge—Carol Kao, MD, Albert Einstein College of Medicine		
	• (19115) Pediatric Unexplained Encephalitis Study (PUES): Next-generation		
	sequencing as a diagnostic modality—Julia Haston, MD, Emory University		
	(19122) CRISPR screening reveals TNF as a mediator of IFN-g induced		
	macrophage death countered by autophagy—Anthony Orvedahl, MD, PhD,		
	Washington University		
	• (19164) Genotypic and phenotypic diversity within the neonatal HSV-2		
	<ul> <li>population—Lisa Akhtar, MD, PhD, Children's Hospital of Philadelphia</li> <li>(19110) Correlating infection phenotypes with tissue viral distribution in</li> </ul>		
	congenital Zika virus infection—Emma Mohr, MD, PhD, University of		
	Wisconsin		
	The contain		
4:00 – 5:00 P.M.	Poster Presentations		
6:30 P.M.	St. Jude/PIDS Reception and Dinner		
	National Civil Rights Museum		

Saturday, March 10	Marlo Thomas Center for Global Education and Collaboration (GEC)	
7:30 A.M.	Breakfast	
8:00 – 9:30 A.M.	<b>Keynote Address</b> Life after respiratory syncytial virus—Fernando Polack, MD, Fundacion, INFANT, Buenos Aires, Argentina	
	Luminary in Pediatric Infectious Diseases  Vaccines and vaccine safety—Larry K. Pickering, MD, Emory University School of Medicine	
9:45 A.M. – 12:30 P.M.	. Career Development Presentations The changing face of Peds ID—Janet Gilsdorf, MD, University of Michigan, Ann A	
	Career Pathways Brief Talks	
	Introduction: Scott James, MD, University of Alabama, Birmingham and Jessica Snowden, MD, University of Arkansas for Medical Sciences	
	Basic Science: George Liu, MD, PhD, Cedars-Sinai Medical Center	
	Outcomes Research: Grace Lee, MD, MPH, Stanford University	
	• Private Practice: Stephanie Stovall, MD, Golisano Children's Hospital of Southwest Florida	
	Public Health at a Local Level: Kari Simonsen, MD, University of Nebraska	
	Career Panel Discussion (11:30 AM – 12:30 PM)	
12:30 – 2:00 P.M.	Lunch and Career Paths Breakout Discussions K Awards/Loan Repayment Program Scott James, MD and Jessica Snowden, MD	
	How Jobs are Pieced Together: Elucidating the Black Box of Peds ID FTE's Kari Simonsen, MD	
	How Grants are Graded: Understanding the NIH Criteria Betsy Herold, MD, Albert Einstein College of Medicine and John Williams, MD, Children's Hospital of Pittsburgh	
2:00 – 3:30 P.M.	Global Health Session Moderators: Miguela Caniza, MD, St. Jude Children's Research Hospital and Miriam Laufer, MD, University of Maryland School of Medicine	
	Part 1: Reflections on careers in global health Vaccines: Edwin Asturias, MD, University of Colorado —Polio and Fernando Polack, MD – RSV	
	Part 2: Global health jeopardy Combination of trivia and cases collected from local and international settings	

## **Table of Contents**

Welcome Letter	iii
Program at a Glance	:
Program at a Glance	IV
General Information	1
Continuing Medical Education Information	2
Presentation Summaries  Invited Speakers/Oral Presenters	4
Poster Presentations	12
Attendee Listing	16
Map of St. Jude Children's Research Hospital	Back Cover

#### **General Information**

#### **Location of Conference**

Marlo Thomas Center for Global Education and Collaboration (GEC) St. Jude Children's Research Hospital 262 Danny Thomas Place Memphis, TN 38105-3678 Headquarter Hotel Information Westin Memphis Beale Street Hotel 170 Lt. George W. Lee Avenue Memphis, TN 38103 (901) 334-5900

## Registration Hours – Marlo Thomas Center for Global Education and Collaboration – St. Jude Children's Research Hospital campus

Wednesday, March 7: 6:00 – 8:00 p.m. (Satellite/Wine Reception – Tennessee Ballroom at the Westin Hotel)

Friday, March 9: 7:00 a.m. – 5:30 p.m. Saturday, March 10: 7:00 a.m. – 4:00 p.m.

#### **Poster Session**

The Poster Session will take place on Friday, March 9, from 4:00 to 5:00 p.m. in the foyer of the GEC building.

#### **Travel Stipend Information**

Recipients of travel stipends must check in at the registration desk each day to verify attendance. Checks can be picked up at the registration desk on the last day of the conference.

#### Mothers' Room

St. Jude Children's Research Hospital offers several Mothers' Rooms around the campus for conference registrants. These rooms can be used to breastfeed your infant or to express and store milk while at the conference. The closest rooms to use during conference hours are the Mothers' Room located at the Chili's Care Center and Danny Thomas Research Center. Please seek staff assistance at the Registration Desk before attempting to use this facility.

#### **Shuttle Bus Service**

Shuttle bus service is available for registrants to St. Jude Children's Research Hospital from the Westin Memphis Beale Street Hotel. Registrants are responsible for providing their own transportation to any other destination while in Memphis. The following shuttle schedule will be posted at the registration desk.

Date	Time	Pick-up Site	Destination
Friday, March 9	7:00, 7:15, and 7:30 a.m.	Westin Memphis Beale Street Hotel	St. Jude
	5:15 and 5:30 p.m.	St. Jude	Westin Memphis Beale Street Hotel
	6:00 p.m.	St. Jude	National Civil Rights Museum
	6:15 and 6:45 p.m.	Westin Memphis Beale Street Hotel	National Civil Rights Museum
	8:30 and 9:00 p.m.	National Civil Rights Museum	Westin Memphis Beale Street Hotel
			and St. Jude
Saturday, March 10	7:00, 7:15 and 7:30 a.m.	Westin Memphis Beale Street Hotel	St. Jude
	3:30 p.m.	St. Jude	Westin Memphis Beale Street Hotel
			and Airport

#### **Friday Night Event**

There will be a tour and dinner at the National Civil Rights Museum on Friday, March 9. The museum is located at 450 Mulberry Street and is within a short distance from the Westin Memphis Beale Street Hotel. A virtual tour of the museum will be taken shortly upon arrival. Dinner will begin after the tour. Roundtrip shuttle bus services will be provided from the Westin and St. Jude. One bus will depart from St. Jude at 6:00 p.m. Another bus will pick up from the Westin at 6:15 and 6:45 p.m. Both buses will return to St. Jude and the Westin beginning at 8:30 and 9:00 p.m.

#### **Internet Access**

St. Jude Children's Research Hospital offers wireless Internet access through HopeNet.

#### **Staff Contact Information**

For onsite assistance, please contact Christy Phillips (202) 306-9545 or Brandi Kirby (901) 595-2641.

#### **Continuing Medical Education Information**

#### **Educational Objectives**

After attending this educational conference, you should be able to:

- Discuss and use new interventions and vaccines for pediatric and prenatal infections
- Compare and contrast different career options in pediatric infectious diseases

Please note that session objectives will be presented during the conference as appropriate.

#### **Accreditation Statement**



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of St. Jude Children's Research Hospital and the Pediatric Infectious Diseases Society. St. Jude Children's Research Hospital is accredited by the ACCME to provide continuing medical education for physicians.

#### **Credit Designation**

St. Jude Children's Research Hospital designates this live activity for a maximum of 13.5 *AMA PRA Category 1 Credits*<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### Acknowledgement

This live activity is supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. The opinions expressed at this conference are those of the faculty and do not necessarily reflect the opinions of the CME provider, joint provider, or commercial supporter.

#### **Evaluation and Credit Certificates**

To claim AMA PRA Category 1  $Credit^{TM}$  or attendance credit for this activity, you must attend the sessions and complete the evaluation by following the instructions below:

- Go to cme@stjude.org
- Sign in using the email address you used when registering for this conference and your password (if you do not remember your password or have not previously used this system, click "forgot my password" and follow the instructions; St. Jude employees should choose "Sign in with your St. Jude ID")
- Click the MyCME button on the top right of your screen and choose Evaluations and Certificates
- Click "Complete Evaluation" by St. Jude/PIDS Pediatric Infectious Diseases Research Conference to complete the evaluation for this activity
- You will then be returned to the Evaluations and Certificates screen to print, download, or email your certificate.

If you have questions about claiming your CME or attendance certificate, please contact us at cme@stjude.org. If you registered after February 28, 2018, or on site, it may take 48 hours to have your information added to the CME system so that you may claim credit.

#### **Disclosure of Financial Relationships**

All individuals in a position to control the content of this CME activity (such as faculty, presenters, and planners) were asked to complete a statement regarding all relevant financial relationships between themselves or their spouse/partner and any commercial interest (defined by the ACCME as "any entity producing, marketing, re-selling, or distributing health care goods and services consumed by, or used on, patients"). St. Jude CME has reviewed and resolved any conflicts of interest that were identified.

All relevant relationships are disclosed on the CME Addendum; no other speakers, planners, or other individuals with control over content have disclosed relevant financial relationships with commercial interests for themselves or their spouse/partner.

#### **Session 1. Frontiers in Infectious Diseases**

Friday, 8:00 - 11:30 a.m.

**GEC** Auditorium

## Using systems serology to understand mother to child antibody transfer GALIT ALTER, Harvard University, Boston, Massachusetts

## Novel therapeutic strategies from study to host-pathogen interaction GEORGE LIU, Cedars-Sinai Medical Center, Los Angeles, California

Major pathogens utilize broad arrays of strategies to overcome host defenses and cause infection. In this presentation, I will describe the pathogenic mechanisms associated with several bacterial factors, including the staphylococcal golden pigment, PBP2a, and GBS hyaluronidase. I will demonstrate how interaction of the pathogenic factors with host immune cells leads to worse infectious outcome and will suggest novel approaches to combat infections based on knowledge of the molecular mechanisms.

## The future of HIV therapeutics, towards sustained ART-free remission and cure DEBORAH PERSAUD, Johns Hopkins University, Baltimore, Maryland

A latent reservoir for HIV-1 resides within memory CD4+ T cells of HIV-1-infected individuals. This stable reservoir precludes virus eradication and cure with current antiretroviral treatment (ART) strategies, rendering antiretroviral treatment life-long. However, a single case of HIV-1-cure in an infected adult, the "Berlin patient", who following treatment of acute myeloid leukemia that included bone marrow transplantation with HIV-1-resistant, CCR5delta32 homozygous cells, has remained off ART for 10 years without return of replicating HIV-1, has transformed the field of HIV-1-therapeutics towards a goal of ART-free HIV-1 remission and cure for infected individuals. Similarly, the single case of 27 months of ART-free remission in a perinatally-infected child, the "Mississippi baby, following very early ART administered within 48 hours of birth, has provided proof-of-concept for ART-free remission in perinatal infection. The novel treatment strategies under clinical investigation towards ART-free remission and cure in pediatric and adult populations will be discussed. The mechanisms underlying the recalcitrant nature of the latent reservoir and their differences in perinatal and adult infection will also be discussed.

## Multidrug resistant enterococci, a problem foreordained by events of the Paleozoic era MICHAEL GILMORE, Harvard University, Boston, Massachusetts

Enterococci are among the most widely distributed core components of gut flora in animals from invertebrates and insects to mammals. This led us to speculate that an ancestral *Enterococcus* colonized the last common ancestor, and was vertically disseminated as new host species evolved. Despite being numerically minor constituents of the gut microbiota, enterococci emerged among the vanguard of multidrug resistant hospital adapted pathogens. Interestingly this happened twice: in *Enterococcus faecalis*, and in the distantly related species *E. faecium*. This raises two questions: 1) What are the core properties of enterococci that make them nearly universal components of gut consortia of such a diverse range of animals? and 2) Why, among the great diversity of gut microbes, did enterococci repeatedly emerge to become leading causes of multidrug resistant hospital acquired infection? With antibiotic resistance now a leading global public health threat, there is a compelling need to understand the underlying biology and genetics that led to their hospital adaptation.

To determine the core traits of enterococci that both enable them to inhabit animals with diverse gut physiologies and diets, and predisposed them to adapt and proliferate in the modern hospital ecology, we selected 25 enterococcal species representing all major phylogenetic branches of the genus. We examined them in detail for phenotype, genotype, and where possible, correlated that with host association. We further compared these traits to those of both commensal and multidrug resistant strains of the most common human

associated species, *E. faecalis* and *E. faecium*. We found that the enterococci acquired the ability to withstand episodic desiccation and starvation, among other stressors, and that speciation is largely driven by changing carbohydrates available in the gut of new hosts. Calibration of divergence indicates that enterococci arose commensurate with the terrestrialization of animals, and parallels their radiation, including gaps as occurred during the Permian Extinction. In adapting to cycles of deposition on land, the enterococci acquired traits that positioned them well for survival and adaptation to the modern hospital environment.

#### Session 1b. 2018 John H. Erskine Lecturer in Infectious Diseases

Friday, 11:30 a.m. – 12:30 p.m.

GEC Auditorium

## Listeria monocytogenes: From basic mechanisms of pathogenesis to cancer immunotherapy DANIEL PORTNOY, University of California, Berkeley

Listeria monocytogenes is an intracellular pathogen that is able to escape from a phagosome, grow rapidly in the host cell cytosol and exploit the host actin cytoskeleton to spread from cell-to-cell without leaving the intracellular environment. This provides a cell biological explanation for the requirement of cell-mediated immunity to clear the infection; i.e., T-cells must be generated that can recognize infected cells and kill the cell. Infection with L. monocytogenes leads to the development of a robust cell-mediated immune response which provides the rationale for using attenuated strains of L. monocytogenes as vaccine vectors. Recombinant strains that express and secrete tumor antigens can stimulate the immune system to recognize and kill the tumor cells.

#### **Lunch – Roundtable with Faculty**

Friday, 12:30 – 1:30 p.m.

GEC Foyer and Board Room

## **Session 2.** Oral Presentations by PIDS and PIDS-St. Jude Fellows and Meeting Attendees Friday, 1:30 – 4:00 p.m.

GEC Auditorium

## Dissecting mechanisms of granulomatous response in chronic bacterial infections TRUNG PHAM, Stanford University, Stanford, California

Infectious granulomas are dynamic microstructures comprised of immune cells and pathogen and are thought to be an important immune response to control chronic latent infections. Mounting evidence suggests granulomatous formation can also serve as a mechanism for pathogen persistence. To study function and regulation of granulomatous response in chronic bacterial infection, we use a latent murine Salmonella infection model with fully virulent bacteria. We find granuloma morphologic maturation temporally coincides with resolution of T-cell IFNy response and reduction of bacterial burden to low chronic stage levels. In lymphoid tissues such as the spleen of chronically infected mice, Salmonella bacilli persist within granuloma microstructures that are predominated by CD11b+CD11c+Ly6C+ myeloid cells. Flow cytometric analyses of splenocytes identify CD11b+CD11c+Ly6C+ cells as granuloma macrophages. Salmonella infection dynamically modulates granuloma macrophage number, phenotype and functions. To define the mechanisms regulating infectious granulomas during chronic Salmonella infection, we disrupt TNFα signaling in infected mice using anti-TNF $\alpha$  monoclonal antibody. TNF $\alpha$  neutralization markedly alters CD11bCD11cLy6C+ macrophage polarization and granuloma cellular organization. Furthermore, mice treated with anti-TNF $\alpha$  antibody exhibit increased bacterial tissue burden and concurrent expansion of IFN $\gamma$ producing T cells. Together our preliminary findings support a model in which TNF\alpha signaling regulates granuloma organization and controls bacterial persistence in chronic Salmonella infection via a CD11b+CD11c+Ly6C+ macrophage-dependent mechanism.

## Development of a consensus DNA vaccine for seasonal H3N2 influenza viruses AMELIA KEATON, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Seasonal influenza is a significant cause of illness worldwide, with children being particularly vulnerable to illness and complications. Available flu vaccines typically induce strain-specific immune responses and therefore must be updated and administered annually. Here we report on the development of a novel seasonal H3N2 influenza vaccine based on synthetic DNA-encoded hemagglutinin (HA) antigens. Initial studies using an animal model indicate that this vaccine platform induces a broadly reactive immune response to a variety of H3N2 viral strains.

## Antibiotic exposure and progression of respiratory viral infections in transplant recipients CHIKARA OGIMI, Seattle Children's Hospital, Seattle, Washington

The objective of this study was to investigate the effect of antibiotic use on the disease progression of subsequent respiratory viral infections (parainfluenza virus, respiratory syncytial virus or human metapneumovirus) in allogeneic transplant recipients. We identified 90 patients (84 adults and 6 children) with first respiratory viral infection during the initial 100 days post-transplantation (6/2008-2/2016). Among these, 33 progressed to lower respiratory tract disease (LRTD). Number of antibiotic-days in the 21 days before viral onset was associated with progression to LRTD after adjusting for neutropenia frequency, steroid use, and either lymphopenia or monocytopenia in Cox proportional hazard models, but use of specific antibiotic classes was not. Cumulative antibiotic exposure immediately prior to viral onset appears to be an important risk factor for the disease progression for some respiratory viruses in transplant recipients.

## IgE-mediated allergic stimulation inhibits monocyte antiviral responses to alter virus-induced T cell priming by influenza and rhinovirus REGINA ROWE, University of Texas Southwestern Medical Center, Dallas, Texas

Respiratory virus infections are highly associated with the development and exacerbation of allergic diseases. Deficient antiviral responses by antigen presenting cells, such as monocytes and dendritic cells, are hypothesized as potential mechanisms underlying this link. Using an *ex vivo* model of primary human monocytes, we evaluated the effects of IgE-mediated allergic stimulation on multiple monocyte functions. Allergic stimulation inhibited virus-induced 1) upregulation of MHC I and II, and co-stimulatory molecules CD80 and CD86, 2) type I interferon release, and 3) CD4 Th1 priming after both influenza A virus and rhinovirus (RV) exposure. Interestingly after RV-exposure, monocytes promoted significant Th2 differentiation, which was further enhanced by IgE-mediated stimulation.

These data suggest that allergic stimulation impairs monocyte innate antiviral responses and results in altered virus-driven T cell differentiation. Modulation of monocyte antiviral inflammatory responses represents another mechanism by which allergic stimulation may contribute to virus-induced exacerbations of allergic disease. An understanding of the molecular mechanisms involved in these processes is ongoing and may identify potential therapeutic targets to prevent allergic disease development, progression, or exacerbation.

## Maternal immunization with $\Delta gD-2$ protects neonatal mice against lethal HSV challenge CAROL KAO, Albert Einstein College of Medicine, Bronx, New York

We hypothesize that maternal transfer of antibodies (Abs) that elicit antibody dependent cellular cytotoxicity (ADCC) will protect neonates from HSV infection. To test this, we compared immunogenicity and efficacy of two vaccine candidates: (i) a single-cycle virus deleted in glycoprotein-D ( $\Delta gD$ -2) that induces high-titer Abs that activate the Fc gamma receptor (Fc $\gamma$ R) to elicit ADCC; and (ii) recombinant gD-2 protein with Alum and MPL adjuvants (rgD-2), which induces primarily neutralizing Abs, but not ADCC.  $\Delta gD$ -2 completely protects adult mice against vaginal or skin challenge with clinical isolates of HSV-1 or 2 and prevents viral latency; rgD-2 provides partial protection, does not prevent latency and failed in clinical trials (ELife, 2014, JCI Insight, 2016, JID, 2017). Methods: C57Bl/6 female mice were vaccinated with  $\Delta gD$ -2 or control uninfected cell lysates or with rgD-2. Mice were mated one week after and pups challenged intranasally with

a lethal dose of HSV on days 1, 7 or 14. To distinguish the roles of transplacental vs. colostrum Abs, motherpup pairs were switched at birth. Results: Pups born and nursed by  $\Delta gD$ -2-immunized mice were protected compared to rgD-2 (p=0.01, Day 7) or control-immunized mice (p< 0.001, Days 7 or 14, Fisher's exact test). Maternal  $\Delta gD$ -2 immunization also prevented or decreased viral dissemination to liver, lung, kidney, brain or trigeminal ganglia. Similar levels of HSV-specific Abs were detected in serum of neonates born to  $\Delta gD$ -2 or rgD-2-immunized mice, but only the former exhibited ADCC. Protection decreased if pups were challenged on Day 1 or were nursed with control mice and correlated with a decline in total HSV-specific and ADCC Abs. Studies are in progress to compare age-related changes in Fc $\gamma$ R expression and ADCC activity. Conclusion: Maternal  $\Delta gD$ -2 vaccination provides significant protection against neonatal infection, which correlates with ADCC.

## Pediatric Unexplained Encephalitis Study (PUES): Next-generation sequencing as a diagnostic modality

JULIA HASTON, Emory University, Atlanta, Georgia

Background: Encephalitis can be associated with focal and global neurologic dysfunction resulting in significant morbidity and mortality in children. Although viruses are often implicated, an etiology is not identified in the majority of cases. Next-generation sequencing (NGS) is a high-throughput metagenomics-based sequencing technique that may enhance the detection of novel or low frequency pathogens.

Methods: Hospitalized immunocompetent patients aged 6 months-18 years with encephalitis of unidentified etiology were eligible for enrollment. Demographic, historical, and clinical information was obtained using a standardized questionnaire. Serum or plasma and cerebrospinal fluid (CSF) samples were subjected to NGS. Pathogens were identified by comparing the nucleic acid sequences from the samples with online databases of sequences.

Results: Twenty patients aged 6 months-17 years and 50% female were enrolled from 2013 to 2017. NGS identified non-human nucleic acid sequences of significant frequency in 4 patients. Those identified by NGS were Cladosporium bantiana in CSF, Mycoplasma bovis in CSF, and Parvovirus B19 in both plasma and CSF, as well as tobacco mosaic virus which was a presumed contaminant. Two organisms diagnosed by conventional CSF PCR, Neisseria meningitidis and Balamuthia mandrillaris, were identified in the NGS data in retrospective analysis. One additional patient was found to have positive IgM serology for LaCrosse virus, but molecular diagnosis was not achieved.

Conclusion: We describe a prospective cohort analysis evaluating NGS as a diagnostic tool for children with unexplained encephalitis. Limitations of NGS in this study included detection of contaminants and difficulty distinguishing low levels of pathogen nucleic acid sequences from background. However, multiple putative pathogens were identified suggesting that NGS could facilitate pathogen discovery and diagnosis.

## CRISPR screening reveals TNF as a mediator of IFN-g induced macrophage death countered by autophagy

ANTHONY ORVEDAHL, Washington University, St. Louis, Missouri

Optimal host immunity rests on a delicate balance between sufficient control of microbial proliferation and limiting injury from the ensuing inflammatory response. Host determinants of this balance are incompletely understood. The cytosolic pathway of autophagy performs important immune functions including degradation of invading pathogens and limiting inflammation. We previously showed that mice lacking autophagy genes in myeloid cells developed hyperinflammation, even under naive conditions. Cells and tissues from autophagy-deficient mice exhibited elevated transcriptional signatures for interferon gamma (IFN-g) and tumor necrosis factor (TNF) pathways. Importantly, the mechanisms driving hyperinflammation in these mice remain obscure. Turning to an in vitro system, we found that cells with CRISPR deletion of autophagy genes were hypersensitive to IFN-g induced cell death. Genome-wide CRISPR screening revealed that TNF pathway genes are required to mediate IFN-g induced death of autophagy gene-deficient cells. Further screen validation and mechanistic experiments will be presented. These studies have potential implications for

improving clinical outcomes in inflammatory states such as sepsis and infections that are controlled by IFN-g and TNF.

## Genotypic and phenotypic diversity within the neonatal HSV-2 population LISA AKHTAR, The Children's Hospital of Philadelphia

Neonates infected with herpes simplex virus (HSV) at the time of birth can have different clinical courses. Approximately half display manifestations limited to the skin, eyes, or mouth (SEM disease, 45%). However, others develop invasive infections that spread systemically (disseminated, 25%) or to the central nervous system (CNS, 30%); both of which are associated with significant morbidity and mortality. The viral and/or host factors that predispose a neonate to invasive forms of HSV infection are not known. To define viral diversity within the neonatal population we evaluated ten HSV-2 isolates cultured from neonates with a range of clinical presentations. To assess viral fitness independent of host immune factors, we measured viral growth characteristics of each isolate in cultured cells and found that they displayed diverse in vitro phenotypes. Isolates from neonates with CNS disease were associated with larger average plaque size and enhanced spread through culture, with isolates derived directly from the cerebrospinal fluid (CSF) exhibiting the most robust growth characteristics. We then sequenced the complete viral genomes of all ten neonatal HSV-2 isolates. We found extensive inter-host variation between isolates distributed throughout the HSV-2 genome. Furthermore, we assessed intra-host variation and found that each HSV-2 isolate contained minority variants, with two viral isolates containing ten-fold higher levels of allelic variation than other neonatal isolates or comparable adult isolates. Several HSV-2 proteins including glycoprotein I (gI, US7), gK (UL53), and viral proteins UL20, UL24, and US2 contained variants that were found only in neonatal isolates associated with CNS disease. These genes encode viral proteins known to contribute to cell-to-cell spread and neurovirulence in mouse models. This study represents the first-ever application of comparative pathogen genomics to neonatal HSV disease.

## Correlating infection phenotypes with tissue viral distribution in congenital Zika virus infection EMMA MOHR, University of Wisconsin, Madison, Wisconsin

Congenital Zika syndrome is a constellation of birth defects that occurs following in utero infection with Zika virus (ZIKV). We hypothesized that higher viral loads and broader viral tissue distribution in the fetus was associated with tissue histopathology and the development of ZIKV-associated birth defects. We developed a nonhuman primate (NHP) model that accurately models human disease with prolonged maternal viremia, vertical transmission, fetal tissue dissemination and birth defects. We infected rhesus macaques with 10<sup>4</sup> PFU of a Puerto Rican ZIKV isolate (PRVABC59) in the first trimester and assessed viral tissue distribution and birth defects in their offspring. We delivered fetuses in the second trimester (n=4) and near term in the third trimester (n=5) to evaluate viral tissue distribution and birth defects. We assessed liveborn infants with a postnatal evaluation that included an ophthalmologic exam, hearing evaluation, electroretinography, visuallyevoked cortical potentials, brain magnetic resonance imaging and neurodevelopmental assessment. Viral RNA was quantified in fetal and infant tissues by QRT-PCR, and for infectious virus by positive- and negative-strand RNA in-situ hybridization. Two dams experienced adverse pregnancy outcomes, with a second trimester stillbirth and a miscarriage near term. Three of 5 infants delivered near term underwent comprehensive postnatal evaluations; one of these experienced respiratory distress requiring noninvasive positive pressure ventilation. One stillborn infant had severe ocular defects consisting of a choroidal coloboma, anterior segment dysgenesis and retinal dysplasia, along with widely disseminated ZIKV infection. Thus, from a total of nine pregnancies evaluated in the study, two had adverse clinical outcomes. Fetal and infant viral tissue distribution analyses are underway to positively correlate viral tissue distribution and ZIKV-associated birth defects.

#### **Session 3. Poster Session**

Friday, 4:00 - 5:00 p.m.

**GEC Foyer** 

#### Session 4. Keynote Address

Saturday, 8:00 – 8:45 a.m.

**GEC** Auditorium

## Life after respiratory syncytial virus FERNANDO POLACK, Fundacion, INFANT, Buenos Aires, Argentina

Respiratory syncytial virus (RSV) is the main cause of hospitalization in infants worldwide. Every year, more than 3 million infants and young children experience severe presentations and an estimated 100,000 children die around the world due to RSV. However, this serious situation is likely to change soon. A number of preventive interventions against the virus are undergoing evaluation in clinical trials and the landscape of respiratory infections may be very different in the next decade.

In this presentation, we will discuss the potential impact of RSV prevention on pediatric hospitalizations, explore whether the virus will be replaced in the respiratory tract by other pathogens, consider the consequences of RSV vaccines for recurrent wheezing and asthma, identify subpopulations that may respond poorly to vaccination, and estimate the impact of a successful vaccine on infant mortality at the hospital and in the community in the developing world.

#### **Session 5.** Luminary in Pediatric Infectious Diseases

Saturday, 8:45 – 9:30 a.m.

**GEC** Auditorium

#### Vaccines and vaccine safety LARRY PICKERING, Emory University, Atlanta, Georgia

Below are the following learning objectives:

- Clarify differences between FDA licensure of and ACIP recommendations for vaccines
- Examine why differences between the two agencies exist
- Review vaccine successes
- Highlight lessons learned from making vaccine recommendation
- Emphasis the role of mentoring in each step of the vaccine development process

#### **Session 6. Career Development Presentation**

Saturday, 9:30 –10:15 a.m.

**GEC** Auditorium

## The changing face of Peds ID JANET GILSDORF, University of Michigan, Ann Arbor, Michigan

Infections have plagued humans since the dawn of time and early physicians recognized patterns of infection and attempted to cure them with remedies we would today consider useless. Eventually, through excellent biomedical research, ID doctors have acquired valuable tools to prevent and/or treat many infections.

As our mastery of the worst infectious diseases evolved, so did the spectrum of research conducted by ID physicians. While we still have much to learn about the basic pathophysiology of, and host responses to,

infections, we also need to know about management of highly immune-compromised patients, effective utilization of medical therapies, and methods to protect patients in our hospitals from infection. To this end, many new opportunities exist in the ways PID physicians are trained, and ithe positions they assume following fellowship.

#### Session 7. Career Pathways Brief Talks/Panel Discussion

Saturday, 10:15 a.m. – 12:30 p.m.

GEC Auditorium

The career pathways session will bring together several faculty members with differing career paths. Each panelist will provide a short talk that introduces the audience to their field and touch on the pros/cons of this career option. After all panelists have given their short talk, they will join each other on stage and answer questions related to career development. There will be a few facilitated questions, but the majority of the discussion will be driven by attendees' questions.

- Basic Science: GEORGE LIU, Cedars-Sinai Medical Center, Los Angeles, California
- Outcomes Research: **GRACE LEE**, Stanford University, Stanford, California
- Private Practice: STEPHANIE STOVALL, Golisano Children's Hospital of Southwest Florida
- Public Health at the Local Level: KARI SIMONSEN, University of Nebraska, Omaha, Nebraska

#### **Session 8. Career Paths Breakout Discussions**

Saturday, 12:30 - 2:00 p.m.

**GEC Conference Rooms** 

#### K Awards/Loan Repayment Program SCOTT JAMES, University of Alabama, Birmingham and JESSICA SNOWDEN, University of Arkansas for Medical Sciences, Little Rock, Arkansas

In this session, faculty will discuss the structure and requirements of the NIH's K series awards (Career Development), as well as the Loan Repayment Program. In addition, Drs. James and Snowden will provide advice on avoiding specific application pitfalls, tips for highlighting the strengths of your application and answer questions from participants on both programs.

## How Jobs are Pieced Together: Elucidating the Black Box of Peds ID FTE's KARI SIMONSEN, University of Nebraska, Omaha, Nebraska

In this session, faculty will discuss the structure of physician salaries, otherwise known as FTE (Full Time Equivalent). We will provide advice on strategies for building the position you need now and in the future, as well as tips on handling common conflicts and concerns. This will be an interactive discussion with ample opportunities for questions.

#### How Grants are Graded: Understanding the NIH Criteria BETSY HEROLD, Albert Einstein College of Medicine and JOHN WILLIAMS, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

In this session, faculty will discuss NIH study section scoring and demonstrate a typical study section discussion of a K award. Topics included will be study section procedures, general approach to reading grants, ways to avoid specific grant pitfalls, and the importance of a clear presentation of your proposed work.

#### Session 9. Global Health Session

Saturday, 2:00 - 3:30 p.m.

**GEC Conference Rooms** 

Moderators: MIGUELA CANIZA, St. Jude Children's Research Hospital, Memphis, Tennessee, and MIRIAM LAUFER, University of Maryland School of Medicine, Baltimore, Maryland

Part 1: Reflections on careers in global health

- Polio Vaccines **EDWIN ASTURIAS**, University of Colorado, Aurora, Colorado
- RSV FERNANDO POLACK, Fundacion, INFANT, Buenos Aires, Argentina

Part 2: Global health jeopardy

• Combination of trivia and cases collected from local and international settings

#### Friday, 4:00 – 5:00 p.m.

<b>Bacterial</b> #19089	An outbreak of pediatric brucellosis in Dallas (Presenter: Linda Hassouneh)
#19099	Diagnosis of a spinal epidural abscess in a neonate by Whole-body magnetic resonance imaging (Presenter: Su Jin Joo)
#19100	Ceftazidime for neutropenic fevers in children: Is it time for a change? (Presenter: Muayad Ali)
#19102	Novel RT-PCR assay for detection of <i>Kingella kingae</i> in children with osteoarticular infections (Presenter: Theresa Madigan)
#19105	Signs of sepsis do not predict SBI or respiratory viral infection rates in febrile infants ≤90 days (Presenter: Erin Nicholson)
#19106	Disseminated multidrugresistant A. Baumanii infection (Presenter Alicia Chang)
#19109	Nasopharyngeal bacterial colonization and AOM in children with RSV acute respiratory infection (Presenter Alejandro Diaz)
#19144	Clinical characteristics of <i>S. aureus</i> bloodstream infections in children (Presenter: Gregory Fricker)
#19112	Clinical course and antibiotic dosing in healthy vs non-healthy weight children with osteomyelitis (Presenter: Joel Waddell)
#19116	Microbiology and susceptibility pattern of skin isolates from patients with epidermolysis bullosa (Presenter: Satja Issaranggoon Na Ayuthaya)
#19118	Predisposing characteristics of pediatric patients for ESBL related urinary tract infections (Presenter: Omayma Amin)
#19119	Comparison of bioMerieux and Roche procalcitonin tests in children with community-acquired pneumonia (Presenter: Sophie Katz)
#19127	Impact of drug resistant bacterial colonization in pediatric hematopoietic cell transplant patients (Presenter: Patrick Gavigan)
#19129	Broad based microbial identification and quantification in low sample volume (Presenter: Mridu Sinha)
#19132	Retapamulin activity against mupirocin-resistant isolates from pediatric patients with MRSA (Presenter: Ami Patel)
#19134	Healthcare associated infections among pediatric patients with neutropenia and cancer in Honduras (Presenter: Pamela Zacasa)
#19142	Surveillance of central line-associated bloodstream infections (CLABSI) and non-
	St. Juda/DIDS Padiatria Infactions Disagge Passageh Conference

	CLABSIs in a pediatric cancer center in a low-resource setting (Presenter: Jose Francisco Mendez)
#19143	Microbiological characteristics of <i>S. aureus</i> isolates in a pediatric hospital in Bogota, 2008-2017 (Presenter: Ivan Gutierrez)
#19149	Human monocytic ehrlichiosis (HME): Mimicker or cause of hemophagocytic lymphohistiocytosis (HLH)? (Presenter: Shaina Hecht)
#19161	Infections in children with acute myeloid leukemia receiving antimicrobial prophylaxis in a tertiary (Presenter: Jennia Acebo)
Host Respon #19091	ses Increase in distal airway mucus-producing Clara-cells during primary <i>Pneumocystis</i> infection (Presenter: Sergio Vargas)
#19101	Kikuchi-Fujimoto disease in children: The forgotten disease (Presenter: Muayad Alali)
#19107	The human antibody response to Enterovirus-D68 iblonfection (Presenter: Matthew Vogt)
#19126	Induction of Muc5b and Muc5ac via STAT6/FoxA2 pathway during <i>Pneumocystis</i> primary infection (Presenter: Diego Rojas)
#19135	Human thoracic duct lymph carries CXCR5++ PD-1++ Tfh to the peripheral blood (Presenter: Laura Vella)
#19137	Reactive hemophagocytic lymphohistiocytosis associated with re-initiation of highly active antiretroviral therapy (Presenter: Melissa Campbell)
#19152	False positive fourth generation combined HIV antigen/antibody immunoassays in patients (Presenter: Julia Haston)
<b>Other</b> #19087	Utility of anaerobic and fungal cultures in clinically ill oncologic patients (Presenter: Madan Kumar)
#19088	A genomic snapshot of the <i>Acinetobacter baumannii</i> lineages circulating in hospitals from Honduras (Presenter: Julio Zuniga)
#19117	Identification of practices for febrile neutropenia in hemto oncology units in Latin America (Presenter: Mario Melgar)
#19125	Towards a unified fever and neutropenia management protocol for Central America and the Caribbean (Presenter: Mario Melgar)
#19128	Impact of time-lapse b/w onset of fever and first I/V Ab in pediatric cancer patients with FN (Presenter: Saadia Anwar)
#19136	Epi info as a toll in antimicrobial stewardship program at a pediatric hospital in Bogoto, Colombia (Presenter: Ivan Gutierrez)

#19160	Evaluation of posaconazole plasma concentrations in pediatric patients (Presenter: Alyssa Berganini)
#19163	Evaluation of the Accelerate Pheno <sup>TM</sup> and its potential clinical impact (Presenter: Jack Schneider)
Other Patl	hogens
#19096	A pathology diagnosis of cutaneous <i>Rhizopus</i> species infection in an adolescent with type 1 diabetes (Presenter: Monika Dietrich)
#19097	Osteomyelitis due to <i>Mycobacterium goodii</i> in an adolescent - case report (Presenter: Alejandro Diaz)
#19108	Cryptococcal brain access in a six-year-old girl (Presenter: Jeffrey Coote)
#19113	Delayed wound healing due to fusariosis following trauma (Presenter: Janitzio Guzman)
#19114	<i>Mucor indicus</i> necrotizing fasciitis in post-stem cell transplant pediatric patient (Presenter: Deborah Bloch)
#19133	Congenital toxoplasmosis in a premature infant, associated with maternal ingestion of deer meat (Presenter: Patricia Pichilingue-Reto)
#19147	Ocular toxocariasis among patients referred for suspicion of retinoblastoma (Presenter: Iván Tinoco Martín)
#19148	Visceral toxocariasis among patients at a pediatric cancer center hospital in Memphis (Presenter: Iván Tinoco Martín)
#19153	Predictive value of noninvasive diagnosis of primary <i>Pneumocystis</i> infection in infants at autopsy (Presenter: Sergio Vargas)
#19158	Identification and characterization of <i>Mycobacterium tuberculosis</i> effector proteins (Presenter: Sujittra Chaisavaneeyakorn)
#19162	Intestinal parasites in pediatric cancer patients in south of Mexico (Presenter: Enid Alejandra Nava)
Viral	
#19069	A unique case of sudden death from pneumonia with superimposed bacterial infection and herpes virus (Presenter: Amit Reddy)
#19083	Hospital acquired viral respiratory infections (HA-VRI) in a tertiary neonatal intensive care unit (Presenter: Claudette Poole)
#19086	Comparison of RSV hospitalized children with and without an underlying medical condition (Presenter: Einas Bataseh)

#19094	Assessing health-related quality of life of pediatric HIV patients in Tabarre, Haiti (Presenter: Aileen Aldrich)
#19103	Acute viral gastroenteritis illness severity by pathogen and rotavirus vaccine status (Presenter: Lubna Hamdan)
#19130	Missed opportunity encounters for early diagnosis of adolscents with HIV infection (Presenter: Lorraine James)
#19146	Use of cyclin-dependent kinase inhibitors to modulate gammaherpesvirus reactivation (Presenter: Joy Hazleton)
#19155	Humoral immune correlates of protection from postnatal CMV acquisition (Presenter: Frances Saccoccio)
#19156	Reception and barriers to long acting injectable ARV for PrEP in adolescent & trainees (Presenter: Aderonke Adefisayo)

#### Abdurrahim, Lukman, MBBS

Boston Medical Center lukman.abdurrahim@bnc.org

#### Acebo, Jennia, MD

Solca Quito joannaacebo@yahoo.com

#### Adefisayo, Aderonke, MD

Stonybrook University Long Island Children's Hospital rorifisayo@gmail.com

#### Akhtar, Lisa, MD, PhD

Children's Hospital of Philadelphia AkhtarL@email.chop.edu

#### Aldrich, Aileen, MD

Children's Hospital and Medical Center aileen.aldrich@unmc.edu

#### Allison, Kim, RN

St. Jude Children's Research Hospital kim.allison@stjude.org

#### Alsulami, Abdulsalam, MD

University of Alabama, Birmingham aalsulami@uabmc.edu

#### Alter, Galit, PhD

Ragon Institute of MGH, MIT and Harvard galter@mgh.harvard.edu

#### Andrews, Shannon, MD

University of Minnesota andre928@umn.edu

#### Anwar, Saadia, MBBS

St. Jude Children's Research Hospital drsdnwr9@gmail.com

#### Bagga, Bindiya, MD

University of Tennessee Health Sciences Center bbagga@uthsc.edu

#### Baquera Arteaga, Maribel, MD

Hospital Infantil del Especialidades del Estado de Chihuahua maribel.baquera@gmail.com

#### Baraldo, Sebastian, MD

Sor Maria Ludovica Children's Hospital sbaraldo@gmail.com

#### Barton, Shanna, MD

University of Louisville smpopi2@gmail.com

#### Becken, Bradford, MD

Duke University Pediatric Infectious Diseases bbecken03@gmail.com

#### Beneri, Christy, DO

Stony Brook Children's Hospital christy.beneri@stonybrookmedicine.edu

#### Bhattacharyya, Arpita, MBBS, DCH, MRCP

Tata Medical Center, Kolkata arpita.bhattacharyya@tmckolkata.com

#### Bhumbra, Samina, MD

Indiana University School of Medicine/The Ryan White Center for Pediatric Infectious Disease and Global Health sbhumbra@gmail.com

#### Bloch, Deborah, MD

Emory University deborah.bloch@emory.edu

#### Bloch, Paul, MD

University of Tennessee pbloch@uthsc.edu

#### Briceno Brito, Eudys, MD

Mount Sinai Kravis Children's Hospital eudys.bricenobrito@mssm.edu

#### Briggs, Benjamin, MD, PhD

University of California, San Francisco benjamin.briggs@ucsf.edu

#### Brizuela, Martin, MD

Helios Salud martin.brizuela1984@gmail.com

#### Burns, Julianne, MD

Children's Hospital of Philadelphia burnsje@email.chop.edu

#### Camelo, Ingrid, MD

Boston Medical Center ingrid.camelo@bmc.org

#### Campbell, Melissa, MD

Yale University melissa.campbell@yale.edu

#### Carrasco, Antonio, MD

Instituto Nacional de Salud del Niño - San Borja antonio1carrasco@hotmail.com

#### Chaisavaneeyakorn, Sujittra, PhD, MD

University of Texas Southwestern Medical Center at Dallas sujittra.chaisavaneeyakorn@UTSouthwestern.edu

#### Chatani, Brandon, MD

University of Miami Miller School of Medicine bchatani@med.miami.edu

#### Cheramie, Martin, M.S.

St. Jude Children's Research Hospital martin.cheramie@stjude.org

#### Coote, Jeffrey, MS

University of Queensland-Ochsner Clinical School v-jcoote@ochsner.org

#### Cortez, Valerie, PhD

St. Jude Children's Research Hospital valerie.cortez@stjude.org

#### Creech, C. Buddy, MD, MPH

Vanderbilt University buddy.creech@vanderbilt.edu

#### Dantuluri, Keerti, M.D.

Vanderbilt University Medical Center keerti.l.dantuluri@vanderbilt.edu

#### Day, Melissa, BS

Vanderbilt University School of Medicine melissa.e.day@vanderbilt.edu

#### Diaz, Tanya, infectious diseases

Hospital Infantil Teleton de Oncologia diaz@hospitalteleton.org.mx

#### Diaz, Alejandro, MD

Nationwide Children's Hospital alejandro.diaz@nationwidechildrens.org

#### Eguiguren, Lourdes, MD

Stanford University luliegui@stanford.edu

#### Elshesheny, Rabeh, PhD

St. Jude Children's Research Hospital Rabeh.elshesheny@stjude.org

#### Espinoza, Darrell, MD

Nicaragua Children Hospital despinoza@ufm.edu

#### Estripeaut, Dora, MD

Hospital del Nino destripeaut@gmail.com

#### Fisher, Brian, DO, MSCE

Children's Hospital of Philadelphia fisherbria@email.chop.edu

#### Flynn, Pat, MD

St. Jude Children's Research Hospital pat.flynn@stjude.org

#### Fortini, Mary, DO

University of Nebraska Medical Center mary.fortini@unmc.edu

#### Foster, Charles, MD

Cleveland Clinic fosterc3@ccf.org

#### Freeman, Alexandra, MD

LCIM/NIAID/DIR/NIH freemaal@mail.nih.gov

#### Gautier, Jacqueline, MD

St. Jude Global jacqueline.gautier@nph.org

#### Gavigan, Patrick, MD

St Jude Children's Research Hospital pgavigan@stjude.org

#### Gilmore, Michael, PhD

Harvard Medical School michael\_gilmore@meei.harvard.edu

#### Gilsdorf, Janet, MD

University of Michigan Medical School gilsdorf@umich.edu

#### Glanternik, Julia, MD

Yale School of Medicine julia.glanternik@yale.edu

#### Goggin, Kathryn, MD

St. Jude Children's Research Hospital kathryn.goggin@stjude.org

#### Gonzalez, Miriam, MD

St. Jude Children's Research Hospital miriam.gonzalez@stjude.org

#### Goulart, Micheline, MD

University of Tennessee mgoulart@uthsc.edu

#### Griffith, Jamilla, MSW

St. Jude Children's Research Hospital jamilla.griffith@stjude.org

#### Grimsley Ackerley, Cassie, MD

Emory University cmgrims@emory.edu

#### Gutierrez, Ivan, MD

Clinica Infantil Colsubsidio ivanfelipegutierrezt@gmail.com

#### Guzman, Janitzio, MD

University of Oklahoma Tulsa janitzio-guzman@ouhsc.edu

#### Halasa, Natasha, MD, MPH

Vanderbilt University natasha.halasa@vanderbilt.edu

#### Hamdan, Lubna, MD

Vanderbilt University Medical Center lubna.r.hamdan@vanderbilt.edu

#### Hassouneh, Linda, MD

University of Texas Southwestern linda hass@hotmail.com

#### Haston, Julia, MD

Emory University juliahaston3@gmail.com

#### Haynes, Andrew, MD

Children's Hospital Coloroado andrew.haynes@childrenscolorado.org

#### Hazleton, Joy, MD, PhD

University of Colorado School of Medicine joy.hazleton@childrenscolorado.org

#### Helgeson, Matt, PharmD

Nabriva Therapeutics m.helgeson.pharmd@gmail.com

#### Hernandez Orozco, Hilda G, MsC

Instituto Nacional de Pediatria wuzhi1916@gmail.com

#### Herold, Betsy, MD

Albert Einstein College of Medicine betsy.herold@einstein.yu.edu

#### Hijano, Diego, MD

St. Jude Children Research Hospital diego.hijano@stjude.org

#### Hobbs, Athena, pharmD

Baptist Memorial Hospital-Memphis athena.hobbs@bmhcc.org

#### Hong, David, MD

Karius, Inc. david.hong@kariusdx.com

#### Hurwitz, Julia, PhD

St. Jude Children's Research Hospital julia.hurwitz@stjude.org

#### James, Scott, MD

University of Alabama, Birmingham sjames@peds.uab.edu

#### James, Lorraine, BS

University of Texas Southwestern Medical Center lorraine.james@utsw.edu

#### Kao, Carol, MD

Albert Einstein College of Medicine ckao@montefiore.org

#### Kashef, Amr, BPharm

Children's Cancer Hospital Egypt 57357 amr.kashef@57357.org

#### Keaton, Amelia, MD

Centers for Disease Control and Prevention keatonaa@gmail.com

#### Khalife, Sara, MD

Brown University sarakhalife7@gmail.com

#### Kilgore, Jacob, MD

Duke University jacob.kilgore@duke.edu

#### Kolaitis, Regina, PhD

St. Jude Children's Research Hospital reginamariakol@hotmail.com

#### Konold, Victoria, MD

University of Chicago vkonold@gmail.com

#### Kumar, Madan, DO

Children's National Medical Center mkumar@childrensnational.org

#### Kumar, Gyanendra, PhD

St. Jude Children's Research Hospital gyanendra.kumar@stjude.org

#### Laufer, Miriam, MD, MPH

University of Maryland School of Medicine mlaufer@som.umaryland.edu

#### Lee, Grace, MD, MPH

Stanford University gmlee@stanford.edu

#### Li, Ying, MD, PhD

St. Jude Children's Research Hospital ying.li@stjude.org

#### Lin, Philana, MD

Children's Hospital of Pittsburgh linpl@chp.edu

#### Liu, George, MD PhD

Cedars-Sinai Medical Center /UCLA george.liu@cshs.org

#### Lloyd, Elizabeth, MD

University of Michigan echenowe@umich.edu

#### Lopez, Santiago, MD

Children's Hospital of Pittsburgh of UPMC Santiago.Lopez@chp.edu

#### Lugo, Debra, MD

Duke University Medical Center debra.lugo@duke.edu

#### Madigan, Theresa, MD

Mayo Clinic madigan.theresa@mayo.edu

#### Mahautmr, Jenvara, BS

St. Jude Children's Research Hospital jenvara.mahautmr@stjude.org

#### Mahmud, Ousman, PhD

St. Jude Children's Research Hospital ousman.mahmud@gmail.com

#### Mandelia, Yamini, MD

Cleveland Clinic mandely@ccf.org

#### Maron, Gabriela, MD

St. Jude Children's Research Hospital gabriela.maron@stjude.org

#### Martin, Kimberly, DO, MPH

OU-Tulsa School of Community Medicine kimberly-martin@ouhsc.edu

#### McElroy, Anita, MD PhD

University of Pittsburgh mcelroya@pitt.edu

#### Melgar, Mario, MD

**UNOP** 

mariomelgart@gmail.com

#### Mentor, Girlande, MD

Hopital Saint Damien/NPFS girlandementor18@yahoo.fr

#### Mohr, Emma, MD, PhD

University of Wisconsin-Madison emohr@uwhealth.org

#### Mukkada, Sheena, MD

St. Jude Children's Research Hospital Sheena.Mukkada@stjude.org

#### Muller, Bill, MD, PhD

Northwestern University/Lurie Children's wjmuller@northwestern.edu

#### Nava, Alejandra, MD

Hospital de Especialidades Pediatricas enidnava@gmail.com

#### Ness, Tara, MD, MPH

Baylor College of Medicine/Texas Children's Hospital tara.ness@bcm.edu

#### OBrien, Brigid, DO

Tulane University bobrien3@tulane.edu

#### Ocampo, Diego, MPH

St. Jude Children's Research Hospital diego.ocampo.bykov@gmail.com

#### Ogimi, Chikara, MD

University of Washington Chikara.Ogimi@seattlechildrens.org

#### Okda, Faten, DVM, MS, PhD

St. Jude Children's Research Hospital faten.okda@stjude.org

#### Orvedahl, Anthony, MD, PhD

Washington University in St. Louis School of Medicine

aorvedahl@wustl.edu

#### Osborne, Christie, MD

University of Colorado/Children's Hospital Colorado

christina.osborne@childrenscolorado.org

#### Pangonis, Scott, MD

Cincinnati Children's Hospital Medical Center Scott.Pangonis@cchmc.org

#### Patel, Ami, MD

New York University School of Medicine ami.patel@nyumc.org

#### Penfold, Catherine, PhD

St Jude Children's Research Hospital catherine.penfold@stjude.org

#### Penton, Manuel, MD

SUNY Downstate / Kings County Hospital manuel.penton@downstate.edu

#### Persaud, Deborah, MD

Johns Hopkins University dpers@jhmi.edu

#### Pham, Trung, MD, PhD

Stanford University tpham8@stanford.edu

#### Pichilingue-Reto, Patricia, MD

University of Texas Southwestern Medical Center

Patricia.Reto@UTSouthwestern.edu

#### Polack, Fernando, MD

**Fundacion INFANT** 

fernando.p.polack@vanderbilt.edu

#### Portnoy, Dan, PhD

University of California, Berkeley portnoy@berkeley.edu

#### Posfay-Barbe, Klara, MD, MS

Children's Hospital of Geneva, University Hospitals of Geneva Klara.PosfayBarbe@hcuge.ch

#### Prestel, Chris, MD

Emory University School of Medicine csprestel@gmail.com

#### Probst, Varvara, MD

Vanderbilt University Medical Center varvara.probst@vanderbilt.edu

#### Rathe, Jennifer, MD, PhD

University of Washington/Seattle Children's Hospital

Jennifer.rathe@seattlechildrens.org

#### Reddy, Amit, MBBS

University of Mississippi Medical Center areddydoc@gmail.com

#### Rodriguez Auad, Juan Pablo, MD

Hospital del Niño Dr. Ovidio Aliaga juparodau@hotmail.com

#### Rojas, Diego, PhD

University of Chile School of Medicine drojass@med.uchile.cl

#### Rosch, Jason, PhD

St Jude Children's Research Hospital Jason.Rosch@stjude.org

#### Rosen, David, MD, PhD

Washington University School of Medicine rosend@wustl.edu

#### Ruderfer, Daniel, MD

Baylor College of Medicine ruderfer@gmail.com

#### Saccoccio, Frances, MD, PhD

Duke University Hospital frances.saccoccio@duke.edu

#### Sanchez, Ivon, MD

Solca Nucleo de Quito sanchezivi@yahoo.com

#### Sanders, Dana, MD

St. Jude Children's Research Hospital dana.sanders@stjude.org

#### Scaggs, Felicia, MD

Cincinnati Children's Hospital Medical Center Felicia.ScaggsHuang@cchmc.org

#### Schneider, Jack, MD

Indiana University School of Medicine jgschnei@iu.edu

#### Sharma, Tanvi, MD, MPH

Boston Children's Hospital tanvi.sharma@childrens.harvard.edu

#### Shekarabi, Emily, MD

Vanderbilt University Medical Center emily.s.shekarabi@gmail.com

#### Simonsen, Kari, MD

University of Nebraska Medical Center kasimonsen@unmc.edu

#### Snowden, Jessica, MD

University of Arkansas for Medical Sciences jsnowden@unmc.edu

#### Soneji, Maulin, MD

Northwestern University masoneji@luriechildrens.org

#### Soni, Priya, MD

University of California, Los Angeles - David Geffen School of Medicine psoni@mednet.ucla.edu

#### Spearman, Paul, MD

Cincinnati Children's Hospital Medical Center paul.spearman@cchmc.org

#### Statler, Victoria, MD, MSc

University of Louisville vastat01@louisville.edu

#### Steinbach, William, MD

Duke University Medical Center bill.steinbach@duke.edu

#### Stronski, Lauren, BSN

St. Jude Children's Research Hospital lauren.stronski@stjude.org

#### Thielen, Beth, MD, PhD

University of Minnesota beth.thielen@gmail.com

#### Tinoco, Ivan, MD

Hospital Universitario Materno Infantil itinoco1985@gmail.com

#### Torres, Dara, MD

Hospital General Tijuana daraofelias@gmail.com

#### Tuomanen, Elaine, MD

St. Jude Children's Research Hospital elaine.toumanen@stjude.org

#### Ulloa, E.R. Chulie, MD, MSc

Children's Hospital of Philadelphia ulloae@email.chop.edu

#### Vargas, Sergio, MD

University of Chile School of Medicine svargas@med.uchile.cl

#### Vaughan, Ana, MD, MPH

Children's Hospital of Philadelphia vaughana@email.chop.edu

#### Vogt, Matthew, MD, PhD

Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center matthew.r.vogt@vanderbilt.edu

#### Voss, Lesley, MBChB

Starship Children's Hospital lesleyv@adhb.govt.nz

#### Waddell, Joel, DO

Children's Mercy Hospital Kansas City jwaddell@cmh.edu

#### Watson, Michael, MD, PhD

University of Michigan mewats@med.umich.edu

#### Wilbur, Christopher, MD

The Children's Hospital of Philadelphia Wilburcj@email.chop.edu

#### Williams, John, MD

Children's Hospital of Pittburgh jvw@chp.edu

#### Wood, James, MD

Indiana University School of Medicine woodjb@iu.edu

#### Yonts, Alexandra, MD

Children's National Medical Center ayonts@childrensnational.org

#### Zahlanie, Yorgo, MD

University of Texas Southwestern Dallas yorgozehlanieh\_6@hotmail.com

#### Zerr, Danielle, MD, MPH

University of Washington/Seattle Children's Hospital danielle.zerr@seattlechildrens.org

#### Zucker, Jason, MD

Columbia University Medical Center jz2700@cumc.columbia.edu


#### Zuniga, Julio, Medical Student

Universidad Catolica de Honduras jczm1991@gmail.com

## Notes

## Notes

## Notes



- **Entrance Gates**
- **Patient Only Parking**

P

Marlo Thomas Center

- Kay Kafe
- Mail Services Center

K

- Docks
- - Danny Thomas/ALSAC Pavilion
  - Patient Care Center
  - **Danny Thomas Research Center** Richard C. Shadyac ALSAC Tower
  - Donald P. Pinkel, MD, Research Tower

  - **Central Energy Plant**
  - AutoZone Garage 1
  - Incinerator/Hazardous Waste
- Kay Research & Care Center Chili's Care Center

  - 088023080 545 Danny Thomas Place
    - 595 Building
    - 505 Building 567 Danny Thomas Place
    - 305 Building
    - Tamer-Rashid (ALSAC HQ)
    - ALSAC HQ Addition
  - Domino's Event Center
- Kmart St. Jude Life Center AutoZone Garage 2
- **Barry Building** Longinotti Building
  - Tri Delta Place
  - St. Jude GMP Facility ALSAC Gift Shop
  - 160 Shadyac Avenue 448 North Second
  - **Data Center** Garage 3
- 655 Warehouse